Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea

References

• Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761–770.
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol. 2012;87:552–554.
   PubMed Web of Science ®Google Scholar
• Verner E, Forsyth C, Grigg AP. Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea. Leuk Lymphoma. 2014;55:1139–1143.
   PubMed Web of Science ®Google Scholar
• Randi ML, Ruzzon E, Luzzatto G, et al. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica. 2005;90:261–262.
   PubMed Web of Science ®Google Scholar
• Tauscher J, Siegel F, Petrides PE. Hydroxyurea induced oscillations in twelve patients with polycythemia vera. Haematologica. 2010;95:1227–1229.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Elliott MA, Kao PC, et al. Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera. Blood. 2000;96:1582–1584.
   PubMed Web of Science ®Google Scholar
• Westerman D, Schwarer A, Grigg AP. Hydroxyurea-induced fever and hepatitis. Aust NZ J Med. 1998;28:657–659.
   PubMedGoogle Scholar
• Alvarez-Larran A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119:1363–1369.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Ruggeri M, Rodeghiero F, et al. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood. 2003;101:3749.
   PubMed Web of Science ®Google Scholar
• Kiladjian J-J, C C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008;22:1990–1998.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418–5424.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126:1762–1769.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013;121: 1720–1728.
   PubMed Web of Science ®Google Scholar
• Gugliotta L, Tieghi A, Tortorella G, et al. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leuk Res. 2011;35:1557–1563.
   PubMed Web of Science ®Google Scholar
• Vannucchi A, Kiladjian J, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372: 426–435.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.
   PubMed Web of Science ®Google Scholar
• Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015;373:920–928.
   PubMed Web of Science ®Google Scholar
• “LeukemiaLeukemia and Haematosarcoma” Cooperative Group EORTC. Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomised trial. Br J Cancer. 1981;44:75–80.
   PubMedGoogle Scholar
• Brodsky I. Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET). Am J Clin Oncol. 1998;21:105–106.
   PubMed Web of Science ®Google Scholar
• van de Pette JEW, Prochazka AV, Pearson TC, et al. Primary thrombocythaemia treated with busulphan. Br J Haematol. 1986;62:229–237.
   PubMed Web of Science ®Google Scholar
• Shvidel L, Sigler E, Haran M, et al. Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia. Leukemia. 2007;21:2071–2072.
   PubMed Web of Science ®Google Scholar
• Berrebi A, Shvidel L, Shtalrid M, et al. Short course of busulphan in essential thrombocythaemia: remodelling of an old strategy. Br J Haematol. 2000;109:249–250.
   PubMed Web of Science ®Google Scholar
• Messinezy M, Pearson TC, Prochazka A, et al. Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre. Br J Haematol. 1985;61:657–666.
   PubMed Web of Science ®Google Scholar
• Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998;91:616–622.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Ruggeri M, Rodeghiero F, et al. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol. 2000;110:577–583.
   PubMed Web of Science ®Google Scholar
• Randi ML, Fabris F, Girolami A. Leukemia and myelodysplasia effect of multiple cytotoxic therapies in essential thrombocythemia. Leuk Lymphoma. 2000;27:279–385.
   Google Scholar
• Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–2232.
   PubMed Web of Science ®Google Scholar
• Barosi G, Besses C, Birgegard G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia. 2007;21:277–280.
   PubMed Web of Science ®Google Scholar
• Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148:961–963.
   PubMed Web of Science ®Google Scholar
• Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829–4833.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108:1497–1503.
   PubMed Web of Science ®Google Scholar
• Kuriakose ET, Gjoni S, Wang YL, et al. JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. Haematologica. 2013;98:e135–e137.
   PubMed Web of Science ®Google Scholar